alexa ABC Subfamily C Member 10 (ABCC10) Is A Promising Novel Target In Hodgkins Lymphoma
ISSN: 2161-1076

Surgery: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

13th International Conference on Surgical Pathology & Practice
March 27-28, 2017 Madrid, Spain

Ghada Mohamed Abdel Salam
National Cancer Institute- Cairo University, Egypt
Posters & Accepted Abstracts: Surgery Curr Res
DOI: 10.4172/2161-1076.C1.030
Abstract
Owing to the progress in its treatment, Hodgkin's lymphoma (HL) has become a potentially curable disease. However, there is a subset of HL patients has disease that is either refractory to treatment or relapses early; outcome for these groups is particularly poor. Moreover, patients receiving combined treatment are at higher risk for second malignancies. ABCC10, also known as multidrug-resistant protein 7 (MRP7), is the tenth member of the C subfamily of the ATP-binding cassette (ABC) superfamily. ABCC10 mediates multidrug resistance (MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor drugs. Our study unveiled for the first time the expression pattern and effect of ABCC10 in Hodgkin's lymphoma (HL). Results of our study showed that ABCC10 is over-expressed in most HL derived cell lines and primary HL tumor cells as compared to normal B cells. Our functional studies showed that inhibition of ABCC10 by one of inhibitor (Tariquidar) had a significant dose-dependent increase in the sensitivity of HL cells to doxorubicin. Importantly, in our study we found that overexpression of TXN was considered to be a negative prognostic factor for HL patients. We showed that there is a significant positive correlation between TXN expression level in tumor cells and tumor stage, that in turn act as a covariant, as it predicted initial response to treatment. These results indicate that ABCC10 plays a role in increasing toxicity of chemotherapy on HL cells, its overexpression affect clinical outcome and it is a potential target in HL.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords